US › Healthcare

Karyopharm Therapeutics Inc (KPTI)

US · Healthcare · Biotechnology

$1.96-0.51%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$35.1M
Revenue YoY
+16.8%
Net profit
$-22.4M
Profit YoY
+4.6%
EPS
$-1.24
EPS estimate
$-1.44
Net margin
-63.9%

EPS came in at -1.24 against a street estimate of -1.44 — a beat of 13.9%.

Key statistics

Market cap
$44.6M
Forward P/E
0.0
P/B
12.05
Book value
$-11.78
EPS (TTM)
$-16.40
52-week high
$10.99
52-week low
$1.80
50-day MA
$8.83
200-day MA
$7.63
Beta
0.94

Analyst view

Analysts rate Karyopharm Therapeutics Inc a buy (6 buy, 1 hold, 0 sell out of 7) with an average price target of $8.67.

Shareholding

Insiders
4.68%
Institutions
84.51%

Largest institutional holders

FundStake
COMMODORE CAPITAL LP8.60%
RA Capital Management, LLC8.46%
Adage Capital Partners Gp LLC7.97%
T. Rowe Price Investment Management,Inc.6.80%
The Goldman Sachs Group Inc4.18%
Avidity Partners Management LP4.09%
Catalio Capital Management, LP3.96%
Squadron Capital Management LLC3.31%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Karyopharm Therapeutics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.